Edgewise Therapeutics logo
Edgewise Therapeutics
EWTX | NASDAQ
Chart Builder DCF Calculator
$43.68
-$2.25 (-4.90%)
At close: Nov 16, 2026, 4:00 PM ET
$43.68
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Edgewise Therapeutics Company Profile

Company profile explained

Company Profile

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

Key Executives

Name Position
Kevin Koch President, Chief Executive Officer & Director
Behrad Derakhshan Chief Operating Officer
Michael Nofi Chief Financial Officer
Alan J. Russell Co-Founder, Chief Scientific Officer & Director
Aylin Tugcu Senior Vice President of Cardiovascular Clinical Development & Medical Affairs
Badreddin Edris Co-Founder & Independent Director
Joanne Donovan Chief Medical Officer
John R. Moore General Counsel
Peter A. Thompson FACP Co-Founder & Independent Chairman

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Aug 17, 2026 4/A [Amend] Filing
Aug 17, 2026 4/A [Amend] Filing
Aug 17, 2026 4/A [Amend] Filing
Aug 17, 2026 4/A [Amend] Filing
Aug 17, 2026 4/A [Amend] Filing
Aug 14, 2026 4 Filing
Aug 14, 2026 4 Filing
Aug 14, 2026 4 Filing
Aug 14, 2026 4 Filing
View All SEC Filings ➞
Edgewise Therapeutics
Edgewise Therapeutics logo
Country United States
IPO Date Mar 26, 2021
Industry Biotechnology
Sector Healthcare
Employees 127
CEO Kevin Koch

Contact Details

1715 38th Street Boulder, Colorado 80301 United States

Stock Details

Ticker Symbol EWTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001710072
CUSIP Number 28036F105
ISIN Number US28036F1057
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.